News

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the promise of continuous ketone monitoring in T1D.

New genome-wide data show AERS+ and AERS− subtypes of major depressive disorder diverge in heritability and metabolic genetic correlations.

In this discussion, Eichenfield discusses which advances in eczema he sees as most impactful and where unmet needs remain for pediatric patients.

The bispecific TSLP/IL-13 inhibitor BEL512 met its primary endpoint and all secondary endpoints in adults with chronic rhinosinusitis with nasal polyps.

DT120 ODT produced a 5.4-point placebo-adjusted HAM-A reduction at week 12 in the phase 3 Voyage trial for generalized anxiety disorder.

Brad Rovin, MD, discusses persistent gaps in IgA nephropathy diagnosis and treatment, from RAS inhibition limits to the promise of B-cell-targeted therapies.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss new insulin pump technology presented at ADCES 2026.

New reviews outline barriers to epinephrine use and support age-specific anaphylaxis recognition criteria in infants and toddlers, says Jay Lieberman, MD.

Rima Rachid, MD, discussed why antibiotic pretreatment before fecal microbiota transplantation may improve peanut allergy response rates.

A pair of clinical forums examined new CKM staging, SGLT2 and MRA trial data, and the barriers delaying heart failure treatment.

In this interview, Lawrence Eichenfield, MD, reviews new data on topical and systemic treatments such as tapinarof and ruxolitinib in atopic dermatitis.

Sonelokimab hit its primary ACR50 end point and all key secondary end points in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial.

Brad Rovin, MD, discusses gaps in IgA nephropathy care, biopsy's expanding role, and how new B cell therapies are reshaping treatment.

Once-weekly insulin icodec hits US pharmacies, simplifying basal dosing for type 2 diabetes with new titration rules and promising A1c results.

Novo Nordisk's once-weekly insulin icodec-abae (Awiqli) has launched nationwide for adults with type 2 diabetes.

The FDA accepted EIT Pharma’s lonafarnib NDA for chronic hepatitis D, supported primarily by the phase 3 D-LIVR trial.

Lawrence Eichenfield, MD, breaks down new AAD pediatric atopic dermatitis guidelines, covering prevention strategies and linked comorbidities.

Diabetes Dialogue hosts recap ADCES26 highlights on insulin delivery tech, CKM care, C-peptide science, ketone monitoring, and hypercortisolism screening.

A genome-wide study of > 460,000 individuals identify 27 loci separating AERS+ and AERS− subtypes of major depressive disorder by metabolic profile.

FDA grants volixibat Breakthrough Therapy and Orphan Drug status for PSC pruritus, but recommends an additional phase 3 trial before NDA.

Resilient Pharmaceuticals has resubmitted its MDMA-assisted therapy NDA for PTSD without a new phase 3 trial, MAPS reported.

Matthew Breeggemann, MD, of UCSF discusses genetic testing, risk stratification, and the future of personalized CKD management in 2026.

Get ahead of the curve with the top 6 trials to watch ahead of ESC 2026.

Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.

Roxana Daneshjou, MD, PhD, outlines steps to close AI equity gaps in dermatology, from diverse data sets to camera testing for skin of color.

Phase 3 LEVEL trial of TNX-103 missed its primary 6MWD endpoint in PH-HFpEF, though a sicker patient subgroup showed benefit versus placebo.

Stay updated with the latest healthcare breakthroughs, including phase 3 sibeprenlimab data in IgAN and the FDA approval of oveporexton for narcolepsy.

Aquestive Therapeutics reported human factors and pharmacokinetic data supporting a planned third-quarter 2026 resubmission of the Anaphylm NDA for Type 1 allergic reactions.